

Summary of the Landscape Analysis of Reproductive & Maternal Health Products in Sub-Saharan Africa

Perrer Tosso, Ph.D.



Our enduring 200-year old mission

Increase the supply of safe, effective **medicines, vaccines, and trusted diagnostics**. USP strengthens health systems at local, regional, and global levels and delivers end-to-end pharmaceutical services that champion **equitable access to quality medical products**.



Assessment of the production of RMH products in SSA



Efforts to increase supply of the **quality-assured products sources** should be **strategic, market-based** and carried out with cross-sectional support.

Landscape Analysis

Study to understand **bottlenecks**, identify existing and potential manufacturers to **build a more reliable and sustainable production in Sub-Saharan Africa**

Products included:

- Oxytocin
- Magnesium sulfate
- Heat-stable carbetocin
- Misoprostol
- Tranexamic acid


1. Identify all manufacturers reproductive maternal health (RMH) product suppliers in SSA.
2. Assess the manufacturers' capacities, including their production capacity, quality assurance (QA) systems, regulatory status, and existing customer base
3. Project the future demand for SSA from major procurers and gaining a greater understanding of private sector demand for these MH supplies in SSA.
4. Compare the regional manufacturing base with the projected demand
5. Identify the significant gaps and challenges to arise from this assessment.
6. Determine the actions and resources to address gaps and challenges effectively.

Snapshot of pharmaceutical manufacturers in Africa



Africa's pharmaceutical manufacturers by country (2020)

Total:600




3 main factors can explain the high concentration of manufacturers in a country:

- Legacy from past industrialization
- National trade and industrial policies
- Strong local demand

- ★ **Focus countries** chosen based on:
- regulatory maturity level,
 - number of manufacturers, and
 - have at least one manufacturer with WHO PQ'ed product

Pharmaceutical manufacturers by ownership (2020)



Summary of RMH products procured by various countries




- Completed the supply data collection in **Ethiopia, Ghana, Kenya, Tanzania, Uganda, South Africa, and Zimbabwe**. The data collected include the **strength, dosage form, supplier and manufacturers countries of origin** of each product.

RMH Product	Ethiopia	Nigeria	Kenya	South Africa	Ghana	Tanzania	Zambia	Zimbabwe	Uganda
Carbetocin Ferring 100 mcg/ ml Inj									
Carbetocin 100 mcg/ml (HS) inj									
Magnesium sulphate 25% inj									
Magnesium sulphate 50% inj									
Misoprostol 25 mcg tablet									
Misoprostol 200 mcg tablet									
Oxytocin 5 iu inj									
Oxytocin 5 iu, Ergometrine 0.5 mg inj									
Oxytocin 10 iu inj									
Tranexamic acid 100 mg/ml inj									
Tranexamic acid 250 mg/5ml inj									
Tranexamic acid 500 mg/5ml inj									
Tranexamic acid 250 mg tablet									
Tranexamic acid 500 mg tablet									

Current reproductive maternal health products manufacturing landscape



Reproductive & maternal health products manufactured in sub-Saharan Africa




- **6 Manufacturers** identified
 - 2 in Nigeria, 2 in Kenya, 1 in South Africa, 1 in Ethiopia
- **Most manufactured product is magnesium sulfate** (5 manufacturers)
- **No producer** of heat-stable carbetocin


We attempted to survey all **6 current manufacturers**. **5 responded** to our survey (**83% response rate**)

We identified companies in **Nigeria** and **Ghana** with plans to begin production of the certain products in the near terms. Their survey is being finalized.

Types of data collected

-  Overall production capacity
-  Production capacity of the RMH products
-  QA & Regulatory compliance indicators
-  Barriers and market dynamics that impact manufacturing of RMH products

Understanding the demand



Challenges and next steps



Challenges – Access to data

Inconsistencies, unavailability, lack of access to registration data from some NRAs

Delayed responses or lack of responses from stakeholders, including manufacturers

Limited access to procurement data (public, private, donors)



Next Steps

Desk Review



Develop tools



Data collection



Data analysis &
complementary
data collection



Report
Due in September



Completed

Ongoing

Thank You

Perrer Tosso, Ph.D.
Director, Pharmaceutical Manufacturing Programs
Email: perrer.tosso@usp.org



Empowering a healthy tomorrow

Questions



Empowering a healthy tomorrow